Fidelity Investments
BCAX

Fidelity Investments’s Bicara Therapeutics BCAX Stock Holding History

Fidelity Investments’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.2M Sell
1,893,070
-207,859
-10% -$4.64M ﹤0.01% 1472
2026
Q1 		$41.8M Sell
2,100,929
-1,246,294
-37% -$21.5M ﹤0.01% 1504
2025
Q4 		$56.3M Buy
3,347,223
+648,862
+24% +$11.1M ﹤0.01% 1396
2025
Q3 		$42.6M Buy
2,698,361
+159,957
+6% +$1.79M ﹤0.01% 1491
2025
Q2 		$23.6M Sell
2,538,404
-1,073,169
-30% -$12.8M ﹤0.01% 1642
2025
Q1 		$47.1M Buy
3,611,573
+1,494,485
+71% +$19.8M ﹤0.01% 1382
2024
Q4 		$36.9M Sell
2,117,088
-156,704
-7% -$3.26M ﹤0.01% 1505
2024
Q3 		$57.9M Buy
+2,273,792
New +$58M ﹤0.01% 1316

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments's BCAX Position: Q2 2026 in Review

Fidelity Investments reduced its Bicara Therapeutics (BCAX) stake by 9.9% in Q2 2026, selling an estimated $4.64M and leaving 1,893,070 shares worth $56.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1472.

Fidelity Investments first reported a position in BCAX in Q3 2024 and has held it in 8 quarters since. The position peaked at $57.9M in Q3 2024. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Fidelity Investments held 1,893,070 shares of Bicara Therapeutics worth $56.2M as of Q2 2026.
  • Fidelity Investments sold 207,859 Bicara Therapeutics shares in Q2 2026, an estimated $4.64M.
  • Bicara Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #1472 holding.
  • Fidelity Investments first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Fidelity Investments's Bicara Therapeutics position peaked at $57.9M in Q3 2024.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.